Morgan Similuk

Morgan Similuk

Auto-generated profile, based on publicly available information

Morgan Similuk

Centralized Sequencing Program, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, Maryland

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2023 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
MGMichael A Gargano
Michael A Gargano
NMNicolas Matentzoglu
Nicolas Matentzoglu
BCBen Coleman
Ben Coleman
EAEunice B Addo-Lartey
Eunice B Addo-Lartey
AAAnna V Anagnostopoulos
Anna V Anagnostopoulos
PRPeter N. Robinson
Peter N. Robinson
The Human Phenotype Ontology (HPO) is a widely used resource that comprehensively organizes and defines the phenotypic features of human disease, enabling computational inference and supporting genomic and phenotypic analyses through semantic similarity and machine learning algorithms. The HPO has widespread applications in clinical diagnostics and translational research, including genomic diagnostics, gene-disease discovery, and cohort analytics. In recent years, groups around the world have developed translations of the HPO from English to other languages, and the HPO browser has been internationalized, allowing users to view HPO term labels and in many cases synonyms and definitions in ten languages in addition to English. Since our last report, a total of 2239 new HPO terms and 49235 new HPO annotations were developed, many in collaboration with external groups in the fields of psychiatry, arthrogryposis, immunology and cardiology. The Medical Action Ontology (MAxO) is a new effort to model treatments and other measures taken for clinical management. Finally, the HPO consortium is contributing to efforts to integrate the HPO and the GA4GH Phenopacket Schema into electronic health records (EHRs) with the goal of more standardized and computable integration of rare disease data in EHRs.

26 March 2018 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
LMLiming Mao
Liming Mao
AKATSUSHI KITANI
ATSUSHI KITANI
MSMorgan Similuk
Morgan Similuk
AOAndrew J. Oler
Andrew J. Oler
LALindsey Albenberg
Lindsey Albenberg
WSWarren Strober
Warren Strober
In these studies, we evaluated the contribution of the NLRP3 inflammasome to Crohn’s disease (CD) in a kindred containing individuals having a missense mutation in CARD8, a protein known to inhibit this inflammasome. Whole exome sequencing and PCR studies identified the affected individuals as having a V44I mutation in a single allele of the T60 isoform of CARD8. The serum levels of IL-1β in the affected individuals were increased compared with those in healthy controls, and their peripheral monocytes produced increased amounts of IL-1β when stimulated by NLRP3 activators. Immunoblot studies probing the basis of these findings showed that mutated T60 CARD8 failed to downregulate the NLRP3 inflammasome because it did not bind to NLRP3 and inhibit its oligomerization. In addition, these studies showed that mutated T60 CARD8 exerted a dominant-negative effect by its capacity to bind to and form oligomers with unmutated T60 or T48 CARD8 that impeded their binding to NLRP3. Finally, inflammasome activation studies revealed that intact but not mutated CARD8 prevented NLRP3 deubiquitination and serine dephosphorylation. CD due to a CARD8 mutation was not effectively treated by anti–TNF-α, but did respond to IL-1β inhibitors. Thus, patients with anti–TNF-α–resistant CD may respond to this treatment option.

10 July 2020 in Science
Verified
Journal Article
Closed access
PDF file
SCSarah A. Cook
Sarah A. Cook
WCWilliam A. Comrie
William A. Comrie
Cecilia Poli-HarloweCecilia Poli-Harlowe
Cecilia Poli-Harlowe
MSMorgan Similuk
Morgan Similuk
AOAndrew J. Oler
Andrew J. Oler
MLMichael J. Lenardo
Michael J. Lenardo
An inherited disorder makes WAVEs: The WAVE regulatory complex (WRC) is a multiunit complex that regulates actin cytoskeleton formation. Although other actin-regulatory proteins modulate human immune responses, the precise role for the WRC has not yet been established. Cook et al. studied five patients from four unrelated families who harbor missense variants of the gene encoding the WRC component HEM1. These patients presented with recurrent infections and poor antibody responses, along with enhanced allergic and autoimmune disorders. HEM1 was found to be required for the regulation of cortical actin and granule release in T cells and also interacted with a key metabolic signaling complex contributing to the disease phenotype. By linking these interactions to immune function, this work suggests potential targets for future immunotherapies. Science , this issue p. 202

16 April 2022 in medRxiv
Verified
Preprint
Open access
PDF file
NVNicole Vasilevsky
Nicole Vasilevsky
NMNicolas A Matentzoglu
Nicolas A Matentzoglu
STSabrina Toro
Sabrina Toro
JFJoseph E Flack
Joseph E Flack
HHHarshad Hegde
Harshad Hegde
JMJulie A McMurry
Julie A McMurry
There are thousands of distinct disease entities and concepts, each of which are known by different and sometimes contradictory names. The lack of a unified system for managing these entities poses a major challenge for both machines and humans that need to harmonize information to better predict causes and treatments for disease. The Mondo Disease Ontology is an open, community-driven ontology that integrates key medical and biomedical terminologies, supporting disease data integration to improve diagnosis, treatment, and translational research. Mondo records the sources of all data and is continually updated, making it suitable for research and clinical applications that require up-to-date disease knowledge.

23 June 2022 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Open access
MSMorgan N. Similuk
Morgan N. Similuk
JYJia Yan
Jia Yan
RGRajarshi Ghosh
Rajarshi Ghosh
AOAndrew J. Oler
Andrew J. Oler
LFLuis M. Franco
Luis M. Franco
MWMagdalena A. Walkiewicz
Magdalena A. Walkiewicz
Prospective genetic evaluation of patients at this referral research hospital presents clinical research challenges. This study sought not only a single-gene explanation for participants' immune-related presentations, but viewed each participant holistically, with the potential to have multiple genetic contributions to their immune phenotype and other heritable comorbidities relevant to their presentation and health. This study developed a program integrating exome sequencing, chromosomal microarray, phenotyping, results return with genetic counseling, and reanalysis in 1505 individuals from 1000 families with suspected or known inborn errors of immunity. Probands were 50.8% female, 71.5% were ≥18 years, and had diverse immune presentations. Overall, 327 of 1000 probands (32.7%) received 361 molecular diagnoses. These included 17 probands with diagnostic copy number variants, 32 probands with secondary findings, and 31 probands with multiple molecular diagnoses. Reanalysis added 22 molecular diagnoses, predominantly due to new disease-gene associations (9 of 22, 40.9%). One-quarter of the molecular diagnoses (92 of 361) did not involve immune-associated genes. Molecular diagnosis was correlated with younger age, male sex, and a higher number of organ systems involved. This program also facilitated the discovery of new gene-disease associations such as SASH3-related immunodeficiency. A review of treatment options and ClinGen actionability curations suggest that at least 251 of 361 of these molecular diagnoses (69.5%) could translate into ≥1 management option. This program contributes to our understanding of the diagnostic and clinical utility whole exome analysis on a large scale.

20 September 2024 in Science
Verified
Journal Article
Closed access
HHHyoungjun Ham
Hyoungjun Ham
HJHuie Jing
Huie Jing
ILIan T. Lamborn
Ian T. Lamborn
MKMegan M. Kober
Megan M. Kober
AKAlexey Koval
Alexey Koval
HSHelen C. Su
Helen C. Su
Humans with monogenic inborn errors responsible for extreme disease phenotypes can reveal essential physiological pathways. We investigated germline mutations in GNAI2 , which encodes G αi2 , a key component in heterotrimeric G protein signal transduction usually thought to regulate adenylyl cyclase–mediated cyclic adenosine monophosphate (cAMP) production. Patients with activating G αi2 mutations had clinical presentations that included impaired immunity. Mutant G αi2 impaired cell migration and augmented responses to T cell receptor (TCR) stimulation. We found that mutant G αi2 influenced TCR signaling by sequestering the guanosine triphosphatase (GTPase)–activating protein RASA2, thereby promoting RAS activation and increasing downstream extracellular signal–regulated kinase (ERK)/mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K)–AKT S6 signaling to drive cellular growth and proliferation.